Loading data for VERA — first visit, this takes a few seconds.

Vera Therapeutics, Inc. (VERA)

NasdaqGM: VERA · 실시간 가격 · USD

35.89

+0.90 (2.57%)

종가 기준: Sep 04, 2026, 3:59 PM

36.00

+0.31%

애프터마켓: 7:30 PM

알림

Alert

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

2.57% (1D)

매수호가	22.14
시가총액	2.59B
매출 (ttm)	n/a
순이익 (ttm)	-402M
	0.95
	-5.87
	n/a
	-7.69
P/B (ttm)	6.33
P/S (ttm)	0.00
실적 발표일	Nov 5, 2026

매도호가	38.91
거래량	1,184,658
평균 거래량 (20일)	2,102,314
시가	34.69
전일 종가	34.99
일중 범위	34.69 - 36.41
52주 범위	22.72 - 56.05
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

VERA 소개

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immuno...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 14, 2021

직원 수 361

상장 거래소 NasdaqGM

티커 VERA

웹사이트 https://veratx.com

전체 기업 정보

재무 실적

2025년 Vera Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -299.62M로, 96.92% 증가했습니다.

재무제표

어닝 서프라이즈

Vera Therapeutics가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -1.52 예상치 상회 0.07, 및 -26.67% 전년 대비 감소.

다음 실적 발표

Vera Therapeutics, Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

주가가 움직인 이유

뉴스

1개월 전 · MarketBeat

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease prog...

1개월 전 · Simply Wall St.

Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?

Vera Therapeutics recently received FDA accelerated approval for TRUTAKNA™ (atacicept-vymj), a first-in-class dual BAFF/APRIL inhibitor to reduce proteinuria in adults with primary IgA nephropathy at ...

1개월 전 · Simply Wall St.

Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval

Vera Therapeutics (VERA) has drawn fresh attention after the US Food and Drug Administration granted accelerated approval for TRUTAKNA to treat adults with IgA nephropathy who are at risk for disease ...

1개월 전 · Simply Wall St.

Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run

Vera Therapeutics has delivered a strong 184.9% return over the past 5 years, yet its valuation checks and current market multiples point to a stock that may now be leaning expensive rather than clear...

2개월 전 · MT Newswires

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

2 페이지 중 1

Vera Therapeutics, Inc. (VERA)